The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review
- PMID: 33868457
- PMCID: PMC8020742
- DOI: 10.1177/17562848211004493
The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review
Abstract
The inflammatory bowel diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), are chronic, progressive, inflammatory conditions of the gastrointestinal tract. Imbalance in the gut microbial community, or dysbiosis, and the subsequent immune response, represent the critical relationship between genetic susceptibility, microbes, and environment factors, that result in IBD. Gastrointestinal pathogens - a common cause of dysbiosis - have been implicated as an environmental trigger in new onset IBD, as well as flare of existing IBD. In this article, we systematically review clinical data regarding the association between specific gastrointestinal pathogens and IBD. Numerous bacteria, viruses, fungi, and parasites have been implicated in the pathogenesis of IBD, and exacerbations of existing disease. In this article, we will also specifically discuss the less recognized microbes that have an inverse association with IBD, including certain bacterial pathogens, such as Helicobacter pylori, and parasites, such as Trichuris species. Future prospective and experimental studies are required to establish causality and clarify potential mechanisms of enteric pathogens in modifying the risk and course of IBD.
Keywords: Enteric infection; flare; gastroenteritis; inflammatory bowel disease; microbiome; mucosal immunology; pathogenesis.
© The Author(s), 2021.
Conflict of interest statement
Conflict of interest: JEA reports receiving research grants from BioFire Diagnostics; consultancy fees or honorarium from BioFire Diagnostics and Janssen; and holds US patent 2012/0052124A1. KC reports receiving research funding from Pfizer, Takeda, and AbbVie; consultancy fees or honorarium from Puretech Health, Genentech, and AbbVie; and holds US patent 10,722,600 and provisional patent 62/935,035. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and holds stock options in Intestinal Biotech Development and Genfit.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
